Severely Ill COVID-19 Patient at Leading Southern California Medical Center Extubated Three Days After Treatment with CytoDyn’s Leronlimab; Two Moderate COVID-19 Patients Removed from External Oxygen Following One Day of Treatment with Leronlimab and Discharged from Hospital Apr 09, 2020 6:00am EDT
CytoDyn Collaborating with U.K.’s Department of Health to Provide Emergency Access to Leronlimab for Severe and Critically Ill COVID-19 Patients Apr 07, 2020 6:00am EDT
First Two Patients Enrolled in Randomized Phase 2, COVID-19 Trial with Leronlimab; Five More Severely Ill COVID-19 Patients Treated Under Emergency IND and Two Patients Have Already Extubated Apr 06, 2020 6:00am EDT
CytoDyn CEO Dr. Pourhassan Appearance on Fox Business Network Rescheduled to April 8 Same Time (11am PT); CytoDyn will Reveal Today the Name of the Hospital and the Physician who Treated 10 Patients During an Interview on Seattle-Affiliate of CBS News which Will Air Between 5-6:30 p.m. PT Apr 03, 2020 1:48pm EDT
CytoDyn Files Request with FDA for Preliminary Meeting for Breakthrough Therapy Designation for Leronlimab in the Treatment of Cancer Apr 03, 2020 6:15am EDT
CytoDyn CEO Dr. Pourhassan to Appear on Fox Business Network Friday, April 3, 2020 at 2:00 pm ET to Discuss Leronlimab Treatment of 10 Severely Ill COVID-19 Patients and Express Appreciation for a Special Hospital, Physician, and Medical Team Who Treated These Patients Apr 03, 2020 6:00am EDT
Treatment with CytoDyn's Leronlimab Indicates Significant Trend Toward Immunological Restoration in Severely Ill COVID-19 Patients Apr 02, 2020 6:00am EDT
CytoDyn Files a Clinical Trial Protocol with the FDA to Treat Severely Ill COVID-19 Patients with Leronlimab where the Primary Endpoint is Mortality Rate at Two Weeks Apr 01, 2020 6:00am EDT
CytoDyn Completes Non-dilutive $15 Million Convertible Note Financing with Conversion Rate at $4.50 Per Share without Warrants Mar 31, 2020 6:15am EDT
